Possible upcoming catalysts! Pay close attention to last paragraph! Hehehe NFA
$Biora Therapeutics (BIOR.US)$ Anticipated Milestones
NaviCap™ Targeted Oral Delivery Platform and BT-600 in ulcerative colitis
Biora will present Phase 1 clinical trial data from the BT-600 program at the American College of Gastroenterology annual meeting in October, 2024.
Initiation of a Phase 1B clinical study in active ulcerative colitis patients is anticipated toward the end of 2024.
BioJet™ Systemic Oral Delivery Platform development
Biora is in active partnership discussions with large pharma and anticipates concluding at least one partnership agreement for the BioJet platform in the near term, with others anticipated later in 2024.
NaviCap™ Targeted Oral Delivery Platform and BT-600 in ulcerative colitis
Biora will present Phase 1 clinical trial data from the BT-600 program at the American College of Gastroenterology annual meeting in October, 2024.
Initiation of a Phase 1B clinical study in active ulcerative colitis patients is anticipated toward the end of 2024.
BioJet™ Systemic Oral Delivery Platform development
Biora is in active partnership discussions with large pharma and anticipates concluding at least one partnership agreement for the BioJet platform in the near term, with others anticipated later in 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
